Several groups have explored the use of adenovirus (AdV
primarily as a replication-defective vector, for gene delivery an
transgeneexpressionofrHAinthehostcells.AdVvectorsinduc
bothcell-mediatedandhumoralimmunityagainsttheexpresse
protein, providing robust protection against the targete
disease39â€“41.However,pre-existingoracquiredimmunityagains
adenovirus can hamper vaccine effectiveness by neutralisin
the vaccine vector and clearing the vector-infected cells. Whil
the use of non-human adenovirus vectors could potentiall
overcome this issue, AdV vector immunity developed throug
repeated immunisation (for example during repeated annua
influenza vaccinations) can dampen the immune respons
against the vaccine antigens39,40.